 Thionucleotides
"Thionucleotides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Nucleotides in which the base moiety is substituted with one or more sulfur atoms.
| Descriptor ID |
D013873
|
| MeSH Number(s) |
D02.886.765 D13.695.900
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thionucleotides".
Below are MeSH descriptors whose meaning is more specific than "Thionucleotides".
This graph shows the total number of publications written about "Thionucleotides" by people in this website by year, and whether "Thionucleotides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 0 | 1 | 1 | | 1990 | 0 | 1 | 1 | | 1991 | 1 | 0 | 1 | | 1993 | 1 | 3 | 4 | | 1994 | 0 | 1 | 1 | | 1996 | 2 | 1 | 3 | | 1997 | 2 | 0 | 2 | | 1998 | 0 | 1 | 1 | | 1999 | 2 | 4 | 6 | | 2000 | 1 | 1 | 2 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 2 | 3 | | 2003 | 0 | 2 | 2 | | 2004 | 2 | 0 | 2 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 1 | 2 | | 2008 | 2 | 1 | 3 | | 2010 | 1 | 2 | 3 | | 2011 | 1 | 0 | 1 | | 2015 | 0 | 1 | 1 | | 2018 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Thionucleotides" by people in Profiles.
-
Yarur AJ, Gondal B, Hirsch A, Christensen B, Cohen RD, Rubin DT. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
-
Patton MH, Roberts BM, Lovinger DM, Mathur BN. Ethanol Disinhibits Dorsolateral Striatal Medium Spiny Neurons Through Activation of A Presynaptic Delta Opioid Receptor. Neuropsychopharmacology. 2016 06; 41(7):1831-40.
-
Hoentjen F, Hanauer SB, de Boer NK, Rubin DT. Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. Dig Dis Sci. 2012 Jan; 57(1):250-3.
-
Li NS, Frederiksen JK, Koo SC, Lu J, Wilson TJ, Lilley DM, Piccirilli JA. A general and efficient approach for the construction of RNA oligonucleotides containing a 5'-phosphorothiolate linkage. Nucleic Acids Res. 2011 Mar; 39(5):e31.
-
Alam-Nazki A, Krishnan J. A mathematical modelling framework for understanding chemorepulsive signal transduction in Dictyostelium. J Theor Biol. 2010 Sep 07; 266(1):140-53.
-
Singer BF, Loweth JA, Neve RL, Vezina P. Transient viral-mediated overexpression of alpha-calcium/calmodulin-dependent protein kinase II in the nucleus accumbens shell leads to long-lasting functional upregulation of alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors: dopamine type-1 receptor and protein kinase A dependence. Eur J Neurosci. 2010 Apr; 31(7):1243-51.
-
Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107. Leuk Lymphoma. 2008 Jul; 49(7):1274-8.
-
Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res. 2008 Apr 15; 14(8):2444-9.
-
Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, Vokes EE. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol. 2008 Feb 20; 26(6):870-6.
-
Moore J, Seiter K, Kolitz J, Stock W, Giles F, Kalaycio M, Zenk D, Marcucci G. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res. 2006 Jul; 30(7):777-83.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|